Bausch Health Companies Inc.
Moat Score — Bausch Health Companies
Total Moat Score
9 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Xifaxan's patent protection and FDA exclusivity within the Salix gastroenterology franchise represent genuine, high-value intangible assets, though most of the rest of the portfolio (branded generics, diversified products) carries little IP protection. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Bausch Health has no meaningful manufacturing or scale cost advantage versus larger, better-capitalized pharma peers, and its heavy debt load actually raises its effective cost of capital relative to competitors. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Xifaxan commands real pricing power as a differentiated, patent-protected therapy, but diversified/branded-generic products face constant payer and generic price pressure. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Pharmaceutical and medical device sales carry no network effect between customers or patients. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Physician prescribing habits and patient treatment continuity create real switching friction for an established therapy like Xifaxan, though switching costs are much lower for commoditized branded-generic products. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The GI specialty-pharma niche Salix operates in supports a limited number of focused competitors, but Bausch Health's broader diversified and international businesses operate in large, fragmented, competitive pharma markets with no efficient-scale protection. |